ACTT-1
In hospitalised adult patients with evidence of lower respiratory tract infection due to COVID-19, is remdesivir superior to placebo in shortening the time to recovery?
Continue reading »Tag: Microbiology
Pandemic Triage
A multicentre evaluation of two intensive care unit triage protocols for use in an influenza pandemic Winston K Cheung. Medical Journal of Australia; August 2012 [3]:178-181. doi:10.5694/mja11.10926] Clinical Question In the event of a viral pandemic, what effect does the use of a triage protocol (specifically the NSW ICU triage protocol) have in increasing ICU bed availability, both in admission […]
Continue reading »FABLED
In patients with severe sepsis what is the sensitivity of blood cultures taken after the initiation of antimicrobial therapy?
Continue reading »LEAP2
Is 5-day oral lefamulin non-inferior to 7-day oral moxifloxacin in the management of community-acquired bacterial pneumonia?
Continue reading »ANTHARTIC
Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest Francois et al. N Engl J Med 2019;381:1831-42. DOI: 10.1056/NEJMoa1812379 Clinical Question In post out-of-hospital cardiac arrest patients treated with targeted temperature management, does the use of empirical antibiotics prevent early ventilator-associated pneumonia? Background Rates of survival to hospital discharge and good neurological outcomes post out-of-hospital cardiac arrest (OOHCA) remain poor Despite […]
Continue reading »SoM
Contact precautions in single-bed or multiple-bed rooms for patients with extended-spectrum Beta-lactamase-producing enterobacteriaceae in Dutch hospitals Kluytmans-van den Bergh. Lancet Infectious Diseases 2019; Published online 23rd August 2019. doi: 10.1016/S1473-3099(19)30262-2. Clinical Question In non-ICU, non-haematology patients that have been identified as carriers of extended-spectrum beta-lactamase-producing enterobacteriaceae (ESBLs), is a strategy of contact precautions in a multiple-bed room compared to contact […]
Continue reading »INSTINCT
In patients with necrotising soft tissue infection (NSTI), does the use of intravenous immunoglobulin (IVIG) compared to placebo improve patient reported physical outcomes?
Continue reading »EMPIRICUS
In non-neutropenic critically ill patients with sepsis, multiple Candida colonisation, and multiple organ failure exposed to broad-spectrum antibacterials, does empirical micafungin therapy compared to placebo increase invasive fungal infection-free survival at day 28?
Continue reading »Talan
In patients with drained cutaneous abscesses does trimethoprim-sulfamethoxazole compared with placebo increase clinical cure rates?
Continue reading »Uranga
In hospitalised patients with community-acquired pneumonia (CAP), is five days of antibiotic therapy non-inferior to standard practice with respect to clinical improvement?
Continue reading »